Companion Diagnostics Market

Global Companion Diagnostics Market Size (2022 to 2027)

As per our recently published report, the global companion diagnostics market size is forecasted to grow USD 12.88 billion by 2027 from USD 4.66 billion in 2022, showcasing a CAGR of 22.56% from 2022 to 2027.

Companion diagnostics are categorized by the rising requirement for improved personalized patient treatment that contributes to healthcare providers and their patients' positive assurance about the treatment results, differing from traditional treatment procedures.

These diagnostics help regulate the patient's personal molecular profile, which supports determining which therapy will work for the patient. This diagnostic procedure requires biopsied tissue to contact the appearance of biomarker protein or mutant. Companion diagnostics are also used in the drug development process by defining a companion biomarker that predicts likely toxicity response. 

MARKET DRIVERS:

The increasing number of targeted therapies, the shifting trend towards personalized medicine, and the rise in the prevalence of improving treatment procedures by properly analyzing diagnosis results are majorly accelerating the growth of the global companion diagnostics market.

In addition, an increase in the focus on next-generation sequencing technology and diagnostics procedures has an immense role in developing drugs, potentially influencing the growth of the global companion diagnostics market.

Furthermore, an increasing number of diagnostic centers with the latest equipment with private and public organizations' help and growing spending on healthcare also fuel the market's growth rate. In addition, companion diagnostics promotes better treatment options suitable for the patient for a particular disease, boosting the global companion diagnostics market.

MARKET CHALLENGES:

However, lack of awareness and skilled professionals and the cost of installing and maintaining the equipment require vast amounts that small-scale companies cannot afford, slowly impeding the market demand.

Frequent changes in the software and the time taken to update the existing one are a little more. This attribute is limiting the demand of the market. In addition, the shortage of skilled technicians to resolve the complications in real-time applications has remained challenging for the market.

Impact of COVID-19 on the global companion diagnostics market:

The global companion diagnostics market growth is negatively impacted during the first quarter of 2020; WHO announced the pandemic as healthcare emergence. When the disease transmission accelerated, all the governments imposed nationwide lockdown. The companion market is significantly affected due to a ban on flights and transportation. Companion market has its supply chain across the country, including significant tier I and Tier II such as Agilent technologies, thermos fisher, Roche Diagnostics, and Abbott laboratories. In the countries such as Europe, Asia Pacific, North America, and South America, suppliers have manufacturing facilities with these countries; due to sudden lockdown and stringent government guidelines and social distancing implementation, the supply chain of these products has been disrupted.

With the surge in the COVID-19 cases, many researchers directed their research to study the novel virus and the disease it causes. In addition, the rising significance of companion diagnostics in drug development and the increasing number of clinical trials for possible drug treatment create the demand for companion diagnostics during COVID-19. The companion diagnostics propel clinical success by identifying biomarkers and disease-specific therapeutic targets. Therefore, the market growth is expected to increase during the forecast period.

REPORT COVERAGE:

This research report on the global companion diagnostics market has been segmented and sub-segmented based on indications, technology, and region.

Companion Diagnostics Market - By Indications:

• Oncology
  • Colorectal Cancer
  • Lung Cancer
  • Breast Cancer
  • Gastric Cancer
  • Melanoma
• Inflammation and Autoimmune Diseases
• Cardiovascular Diseases
• Central Nervous System Disorders
• Virology Diseases

Oncology is the highest revenue-creating segment based on indications as most of the companion diagnostics have been developed to detect one or the other cancer biomarkers. Oncology held the most significant market shares in this market in 2020 and is likely to continue the same trend during the forecast period. Due to the growing occurrence of cancer worldwide, increasing part of companion diagnostics in raising awareness about the humanizing medicine treatment of cancer helps the oncology segment grow. Growing benefits of biomarkers for the diagnosis of cancer and also advanced technology in cancer diagnostics and treatment.

Within oncology, lung cancer is the most common cancer found in people worldwide and is likely to grow faster in the forthcoming years.

Companion Diagnostics Market - By Technology:

• Immunohistochemistry
• Molecular Diagnostics
  • In-Situ Hybridization
  • Real-Time PCR
  • Gene Sequencing

Based on technology, the molecular diagnostics segment accounts to hold the highest share during the forecast period. In this technology, the Real-Time PCR segment is likely to continue its growth during the period. This PCR is used to identify the causes of many diseases, which is the primary force driving this segment's growth.

The gene Sequencing segment is expected to showcase decent CAGR during the forecast period due to the potentiality of sequence thousands of genes.

Companion Diagnostics Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Regionally, North America accounted for the leading share in the global companion diagnostics market in 2020, with revenue rise in developed and developing countries. In addition, the adoption of advanced technologies and the launch of various equipment favoring the end-user are further gearing up the market growth in North America. As a result, the U.S. companion diagnostics market is predicted to grow at a significant CAGR during the forecast period, and Canada is expected to showcase a healthy CAGR. 

The European market is positioned next to North America in accounting for the majority share in the global market in 2020. The rise in the number of patients with different diseases like cancer, cardiovascular, and others fuels the market's growth. Also, increasing knowledge over launching companion diagnostics procedures for various applications is prompting the market's demand. As a result, EU Countries such UK, Germany, and France are estimated to register the most significant share in the European market during the forecast period.

Asia Pacific has witnessed a tremendous growth rate from the past decade and is also deemed to hit the highest CAGR in foreseen years. The growing use of biomarkers for various purposes in the medical sector is lavishing the market's demand. In the APAC region, India is predicted to register a promising CAGR during the forecast period. Other countries such as China, Japan, and Australia are estimated to be growing at a healthy rate from 2021 to 2026.

The Latin American region is projected to be growing at a CAGR of 22.83% during the forecast period.

The Middle East and Africa are to have a positive growth rate shortly with the rising support from the government by introducing reimbursement schemes to allow quality treatment for ordinary people.

KEY MARKET PLAYERS:

Most promising companies operating in the global companion diagnostics market profiled in this report are Abbott Molecular Inc., Roche Molecular Systems Inc., Leica Biosystems Nussloch GmbH, bioMérieux Inc., Dako Inc., Qiagen Ltd., ARUP Laboratories, Myriad Genetics Inc., Biogenex Laboratories Inc., Ventana Medical Systems Inc., and Thermo Fisher Scientific Inc.

RECENT HAPPENINGS IN THE COMPANION DIAGNOSTICS MARKET:

• In May 2020, Myriad received the FDA clearance for mychoice CDx as a companion diagnostic for Lynparza. It is for women who have ovarian cancer. The acceptance of mychoice helps the clinicians identify the women with ovarian cancer whose HRD is positive and responds to the therapy. 
• In April 2019, Qiagen launched the novel therascreen FGFR RGQ RT-PCR kit that works as a companion diagnostic. It is the first FDA approved to treat Mestastatc Urothelial Cancer. 
• In June 2015, the Ventana medical system (a part of Roche Group) had received FDA clearance for VENTANA ALK (D5F3). It is a companion diagnostic that helps trigger lung cancer patients for Pfizer's FDA-approved targeted therapy, XALKORI.